, 1999). ently insensitive to chemotherapeutic agents and others
Instead, ARF is induced by mitogenic oncogenes, peracquire resistance upon relapse. Most conventional haps as part of a failsafe mechanism that counters agents damage cellular components, often DNA, and hyperproliferative signals (Sherr, 2001a) . By contrast, for years it was assumed that this damage was directly p16 INK4a is a cyclin-dependent kinase inhibitor that proresponsible for their anti-tumor effect ( natural site. E-myc transgenic mice overexpress the , and the resulting B-cell malignancies resemble human non-Hodgkin's lymphomas. We previously develPrevious studies have shown that GFP can be visualized in tumor xenografts by whole-body fluorescence oped methods for rapidly producing E-myc lymphomas with compound genetic lesions, as well as strategies imaging (Yang et al., 2000) . Here, manifestations of GFPtagged E-myc lymphomas were readily visualized in for studying treatment responses that parallel clinical trials (Schmitt et al., 1999 (Schmitt et al., , 2000b (Schmitt et al., , 2002 . As in human the lymph nodes (LN), bone, and other organs of recipient mice-precisely matching the anatomical locations cancers, mutations that disrupt p53 or the INK4a/ARF locus compromise therapy in E-myc lymphomas predicted from pathological evaluation ( Figure 1A ). Lymphoma-bearing mice were treated with cyclophospha-(Schmitt et al., 1999). Therefore, using this system, the biologic and genetic determinants of drug action can mide (CTX), an alkylating agent that is used against lymphomas and other malignancies. Ctrl.-MSCV tumors be studied in a relevant setting, yet in a manner not possible in patients. Here, we use the E-myc model to typically responded rapidly to CTX, with no GFP fluorescence detectable by 24 hr or thereafter ( Figure 1A) . In explore the biologic and genetic basis for drug action and drug resistance, and find that a senescence procontrast, p53 null-MSCV tumors underwent a delayed response, and invariably relapsed ( Figure 1A ). Remarkgram controlled by p53 and p16
INK4a is an important determinant of treatment outcome in vivo.
ably, ctrl.-bcl2-transduced tumors displayed virtually no response to CTX, even though it was administered at the maximum tolerated dose. The initial response of Results these tumors parallels what has been observed in mouse cohorts (Schmitt et al., 1999 (Schmitt et al., , 2000b , and indicates that Nonapoptotic Functions of p53 Contribute to Treatment Outcome CTX action engages both p53-dependent and independent apoptotic programs. The ability of p53 to induce apoptosis in response to DNA damage is considered an important determinant Although the ctrl.-bcl2 tumors failed to regress following therapy, they did not progress for extended periods of drug action. Concordantly, both loss of p53 and overexpression of Bcl2 (which acts downstream of p53 to ( Figure 1A ). This is in marked contrast to p53 null-MSCV and p53 null-bcl2 tumors, which progressed rapidly (Figsuppress apoptosis) compromise therapy in E-myc lymphomas (Schmitt et al., 1999 (Schmitt et al., , 2000b . To compare ure 1A, and data not shown). To extend these results, we compared the tumor-free survival (i.e., time-to-relapse) and contrast the impact of these lesions on treatment sensitivity, we generated a panel of primary lymphomas and overall survival of CTX-treated mice harboring tumors lacking p53 or overexpressing Bcl2. As expected, with defined genetic lesions (Schmitt et al., 2000b) . We introduced retroviral vectors expressing green fluoresboth lesions prevented mice from achieving long-lasting remissions ( Figure 1B ; compare to ctrl.-MSCV). Howcent protein (GFP) alone (MSCV), or coexpressing Bcl2 and GFP (MSCV-bcl2), into primary E-myc lymphomas ever, mice harboring ctrl.-bcl2 lymphomas lived much longer than mice with p53 null lymphomas ( Figure 1B ; arising in control (ctrl.) or p53 ϩ/Ϫ animals. Note that lymphomas arising in p53 ϩ/Ϫ mice invariably lose the wildp Ͻ 0.0001, e.g., at 30 days: Ͼ75% overall survival for ctrl.-bcl2 versus 0% for both p53 null groups). Bcl2 did type p53 allele and become p53 null. This procedure produced four lymphoma populations, designated as not affect overall survival in the p53 null group, implying that neither its potential role in delaying cell-cycle entry ctrl.-MSCV, ctrl.-bcl2, p53 null-MSCV, and p53 null-bcl2, respectively (Table 1) 
immunoprecipitation (IP) preceding immunoblotting (right). (B) p16
INK4a immunohistochemistry (IHC) in a representative ctrl. HSC -bcl2 lymphoma sample generated as in (A), (medium power field; high power inlay shows nuclear reactivity). then injected into syngeneic recipients, and the lym-5B). Importantly, ARF was not required for p16 INK4a induction, since CTX also induced p16
INK4a in ARF null lymphophoma-bearing mice were either left untreated (ut) or were treated with CTX. Whereas the untreated lymphomas expressing Bcl2 ( Figure 5A ). Paradoxically, p16
INK4a levels were extremely high in p53 null lymphomas overmas retained exon 2, the CTX-treated tumors did not ( Figure 4C, compare lanes 3 and 4) . Therefore, the expressing Bcl2, and these levels further increased in response to CTX ( Figure 5A) INK4a levels were examined in transplanted ARF during CTX therapy, and vice versa. Indeed, p53 null;INK4a/ARF ϩ/Ϫ lymphomas (generated by intercrossctrl. HSC -bcl2 lymphomas before and after CTX therapy. As was observed for p53 (see Figure 2B) , 1995) . Most importantly, however, the program CTX depends on its ability to induce both apoptosis and senescence. Tumors lacking both programs rapidly is controlled by the p53 and p16/Rb tumor suppressor pathways (Campisi, 2001 ).
progress to a lethal stage, suggesting that post-damage responses are almost completely responsible for CTX To determine whether CTX-induced cytostasis has features of cellular senescence, we examined SA-␤-gal action. Together, our results establish a paradigm for understanding drug action, as well as the interconnecactivity in ctrl. HSC -bcl2 lymphomas. These lymphomas were chosen because they respond to CTX by a celltions between tumorigenesis and drug resistance. This paradigm will undoubtedly apply to other conventional cycle arrest involving p53 and p16 INK4a (see above). Individual samples were transplanted into several recipients anticancer agents, and perhaps many "targeted therapeutics." each, and SA-␤-gal activity was examined in lymphoma sections at various times post-treatment. SA-␤-gal activity was not detected in untreated lymphomas, but Senescence Contributes to Treatment Outcome Our study provides direct evidence that cellular senesprogressively accumulated between 1 and 2 days posttherapy (data not shown), achieving extremely high levcence can be induced following chemotherapy in vivo, Figures 2, 5, and 7) . Disruption of either p53 or INK4a disabled the arrest program, prevented SA-␤-gal accumulation, and acquired loss of either gene often accompanied progression of once dormant tumors to a terminal stage (Figures 2, 5, and 7) . The latter observation is consistent with the possibility that CTXinduced cytostasis is stable, and its escape requires rare pre-existing mutations that disable the program. Importantly, the senescence program contributed to treatment outcome, since mice harboring tumors capable of senescence but not apoptosis had a substantially better post-therapy prognosis than those harboring tumors with defects in both processes (Figures 1 and 3) .
Cellular senescence may parallel apoptosis as a global response to stress. Indeed, we see that both apoptosis and senescence contribute to drug action, and that loss of either process promotes treatment failure. Interestingly, certain agents that trigger apoptosis in one cell type induce senescence in another, and p53 and the INK4a/ARF locus encode important regulators of both processes. Why some cells undergo apoptosis while others senesce is not known, but we note that drug-induced senescence is most pronounced in the presence of an apoptotic block. This suggests that senescence can serve as a "backup" to apoptosis, and may explain the inability of Bcl2 to enhance clonogenic survival following drug treatment in vitro (Brown and Wouters, 1999) . This backup may be particularly important in cell types not naturally prone to apoptosis or in solid cancers that have acquired an apoptotic block during the course of tumor evolution. Figure 4) . another of these byproducts-defects in cellular senescence-supplies an additional capability to a tumor that Hence, the precise way in which ARF is mutated during lymphomagenesis has a profound impact on treatment is revealed only under therapy. This capability is not conferred to control E-myc lymphomas overexpressoutcome-mice harboring tumors that have disrupted both genes have a worse prognosis than those with ing Bcl2, despite their equally aggressive pre-treatment behavior. Similarly, ARF loss completely disables p53 tumors lacking ARF alone. during lymphomagenesis, yet allows p53 activation during therapy (see Figure 7C) . Consequently, ARF null tuMouse Models as Test Systems to Study mors respond better to chemotherapy than p53 null tuDrug Action mors (Figures 1 and 3) . Therefore, the precise way in
p53 Action in Mediating Treatment Responses
The E-myc model provides a unique setting to study which the p53 pathway is disabled during tumorigenesis drug action (Schmitt et al., 2000a) . In this study, we can give rise to heterogeneity in treatment responses.
introduced transgenes into hematopoietic stem cells from different genetic backgrounds to rapidly produce tumors with compound genetic lesions, and tagged lymINK4a/ARF Locus and Cancer Therapy phoma cells with GFP to monitor treatment responses Our data provide the first demonstration that p16 INK4a in vivo by fluorescence imaging. These approaches alcontributes to treatment outcome in vivo, and imply that lowed us to dissect the biologic and genetic determithis reflects its pro-senescence activity. First, tumors nants of drug action in a manner that would be impossiwith engineered or spontaneous mutations disrupting ble using cell lines or in patients. For example, this both INK4a and ARF are less responsive than those system allowed us to spatially and temporally monitor harboring ARF mutations alone (Figures 3 and 4 INK4a induces cell-cycle arrest through the p53 pathway; rather, we suspect that these molecules coopapoptosis during tumor development can simultaneously select for drug resistant cells (Schmitt et al., 1999 ). erate such that intact p53 function makes the cell permissive for the p16 INK4a effect ( Figure 7C ). Interestingly, This observation provides one explanation for intrinsic drug resistance-i.e., resistance with no preceding drug p53 initiates, but does not maintain, senescence in murine fibroblasts (Ferbeyre et al., 2002) , and it is possible exposure. In this study, we identify an unexpected twist to this relationship. We see that byproducts of tumor that p16
INK4a contributes to the maintenance process. The way in which the INK4a/ARF locus is mutated development-i.e., genetic changes not selected for during tumor evolution-can give rise to acquired capaduring tumor development produces heterogeneity in treatment responses. ARF mutations promote lymphobilities that become relevant only under therapy. This may be because the different components of the tumor magenesis, whereas INK4a mutations (alone or in com-
